JP2019514367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514367A5 JP2019514367A5 JP2018555114A JP2018555114A JP2019514367A5 JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5 JP 2018555114 A JP2018555114 A JP 2018555114A JP 2018555114 A JP2018555114 A JP 2018555114A JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5
- Authority
- JP
- Japan
- Prior art keywords
- imp
- protein
- eev
- fragment
- vaccinia virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018697 Membrane Proteins Human genes 0.000 claims 29
- 108010052285 Membrane Proteins Proteins 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 241000700618 Vaccinia virus Species 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 150000007523 nucleic acids Chemical group 0.000 claims 13
- 239000012528 membrane Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 101150073066 F13L gene Proteins 0.000 claims 5
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 claims 5
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 claims 5
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000035085 multipass transmembrane proteins Human genes 0.000 claims 3
- 108091005494 multipass transmembrane proteins Proteins 0.000 claims 3
- 102220477045 Dynein axonemal assembly factor 10_A56R_mutation Human genes 0.000 claims 2
- 101150039660 HA gene Proteins 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 108700029871 Vaccinia virus 42kDa Proteins 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 210000002845 virion Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101150115056 A31R gene Proteins 0.000 claims 1
- 101150108168 A33R gene Proteins 0.000 claims 1
- 101150049392 A34R gene Proteins 0.000 claims 1
- 101150076005 A36R gene Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100039820 Frizzled-4 Human genes 0.000 claims 1
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 claims 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 claims 1
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims 1
- 101100000236 Vaccinia virus (strain Western Reserve) VACWR159 gene Proteins 0.000 claims 1
- 101900242771 Vaccinia virus Protein A33 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 102000052343 human FZD4 Human genes 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077485A JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326501P | 2016-04-22 | 2016-04-22 | |
| US62/326,501 | 2016-04-22 | ||
| PCT/US2017/028787 WO2017184951A1 (en) | 2016-04-22 | 2017-04-21 | Integral membrane protein display on poxvirus extracellular enveloped virions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077485A Division JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514367A JP2019514367A (ja) | 2019-06-06 |
| JP2019514367A5 true JP2019514367A5 (cg-RX-API-DMAC7.html) | 2020-05-28 |
| JP7072521B2 JP7072521B2 (ja) | 2022-05-20 |
Family
ID=60116403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555114A Active JP7072521B2 (ja) | 2016-04-22 | 2017-04-21 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
| JP2022077485A Pending JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077485A Pending JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Country Status (20)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX353352B (es) | 2009-05-08 | 2018-01-10 | Vaccinex Inc | Anticuerpos anti-cd100 y metodos para su uso. |
| PT2766093T (pt) | 2011-10-11 | 2018-05-18 | Vaccinex Inc | Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| ES2782834T3 (es) | 2013-06-25 | 2020-09-16 | Vaccinex Inc | Uso de moléculas inhibidoras de semaforina-4D en combinación con una terapia inmunomoduladora para inhibir el crecimiento tumoral y la metástasis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3494131B1 (en) | 2016-08-02 | 2024-09-18 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN109706177A (zh) * | 2019-01-24 | 2019-05-03 | 浙江省医学科学院 | 一种重组痘苗病毒表面展示系统载体质粒及应用 |
| EP4043482A4 (en) * | 2019-10-02 | 2024-03-13 | Bionoxx Inc. | TUMOR TARGETING PROTEIN OR ASSOCIATED FRAGMENT, ANTIBODIES BINDING THEREWITH AND ITS USE |
| CN115996948A (zh) * | 2020-05-06 | 2023-04-21 | 瓦西尼斯公司 | 痘病毒胞外包膜病毒颗粒上的整合膜蛋白展示 |
| CN116710476A (zh) * | 2020-07-14 | 2023-09-05 | 豪夫迈·罗氏有限公司 | 用于固定剂量组合的测定 |
| AU2021308283A1 (en) * | 2020-07-14 | 2023-02-02 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| KR102739298B1 (ko) * | 2021-04-02 | 2024-12-06 | 주식회사 바이오녹스 | 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편 |
| KR102419397B1 (ko) * | 2021-04-02 | 2022-07-14 | 주식회사 바이오녹스 | 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 |
| EP4536698A1 (en) | 2022-06-10 | 2025-04-16 | Vaccinex, Inc. | Methods to select antibodies specific to complex membrane antigens |
| EP4626914A1 (en) * | 2022-11-29 | 2025-10-08 | Malcorp Biodiscoveries Limited | Novel cd20 protein |
| CN116218879B (zh) * | 2022-12-28 | 2025-09-09 | 中国人民解放军军事科学院军事医学研究院 | 一种单价广谱的正痘病毒属mRNA疫苗及其应用 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| EP0897980A3 (en) * | 1997-08-20 | 2002-04-17 | Smithkline Beecham Corporation | CXCR4B: A human splice variant of CXCR4 chemokine receptor |
| WO2000028016A1 (en) | 1998-11-10 | 2000-05-18 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US7198920B1 (en) * | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| US20040014033A1 (en) * | 1999-06-30 | 2004-01-22 | Evotec Biosystems Ag, A Corporation Of Germany | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| JP2003504014A (ja) * | 1999-06-30 | 2003-02-04 | エボテック オーアーイー アクチェンゲゼルシャフト | ウイルス状粒子、それらの調製及び好ましくは薬学的スクリーニング及び機能的ゲノムにおけるそれらの使用 |
| DE60126130T2 (de) | 2000-11-17 | 2007-10-18 | The University Of Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US20030044409A1 (en) * | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| US20060003316A1 (en) | 2002-07-15 | 2006-01-05 | John Simard | Immunogenic compositions derived from poxviruses and methods of using same |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| CA2503390A1 (en) * | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| US20050158323A1 (en) | 2003-12-04 | 2005-07-21 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| WO2006026389A2 (en) | 2004-08-27 | 2006-03-09 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| EP2290087A3 (en) * | 2004-12-22 | 2011-06-15 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| CA2678618C (en) | 2007-02-21 | 2019-03-12 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cd1d molecules |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| EP2237792B1 (en) | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| AU2009303788B2 (en) | 2008-05-28 | 2015-02-05 | Inovio Pharmaceuticals, Inc. | Smallpox DNA vaccine and the antigens therein that elicit an immune response |
| DK2385980T3 (en) | 2009-01-08 | 2018-07-30 | Albert Einstein College Medicine Inc | BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF |
| MX353352B (es) | 2009-05-08 | 2018-01-10 | Vaccinex Inc | Anticuerpos anti-cd100 y metodos para su uso. |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| CA2804029A1 (en) | 2010-07-07 | 2012-01-12 | Steven A. Porcelli | Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
| CA2810217C (en) | 2010-09-02 | 2019-03-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| PT2766093T (pt) | 2011-10-11 | 2018-05-18 | Vaccinex Inc | Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) * | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| ES2782834T3 (es) | 2013-06-25 | 2020-09-16 | Vaccinex Inc | Uso de moléculas inhibidoras de semaforina-4D en combinación con una terapia inmunomoduladora para inhibir el crecimiento tumoral y la metástasis |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3158058B1 (en) * | 2014-06-18 | 2019-04-17 | MorphoSys AG | Fusion proteins and uses thereof |
| EP3494131B1 (en) | 2016-08-02 | 2024-09-18 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| US11572408B2 (en) | 2017-03-20 | 2023-02-07 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent |
| BR112019023138A2 (pt) | 2017-05-05 | 2020-07-28 | Vaccinex, Inc. | anticorpo 4d anti-semaforina humano |
-
2017
- 2017-04-21 CN CN202211138346.9A patent/CN116286909A/zh active Pending
- 2017-04-21 KR KR1020187033790A patent/KR102558637B1/ko active Active
- 2017-04-21 PL PL17786694.4T patent/PL3445397T3/pl unknown
- 2017-04-21 CN CN201780025118.1A patent/CN109069613B/zh active Active
- 2017-04-21 NZ NZ786461A patent/NZ786461A/en unknown
- 2017-04-21 ES ES17786694T patent/ES2935585T3/es active Active
- 2017-04-21 IL IL262232A patent/IL262232B2/en unknown
- 2017-04-21 SG SG11201808554TA patent/SG11201808554TA/en unknown
- 2017-04-21 RU RU2018140971A patent/RU2759846C2/ru active
- 2017-04-21 US US16/091,077 patent/US10577427B2/en active Active
- 2017-04-21 EP EP17786694.4A patent/EP3445397B1/en active Active
- 2017-04-21 AU AU2017252427A patent/AU2017252427B2/en active Active
- 2017-04-21 WO PCT/US2017/028787 patent/WO2017184951A1/en not_active Ceased
- 2017-04-21 MX MX2018012818A patent/MX388030B/es unknown
- 2017-04-21 EP EP22165288.6A patent/EP4059516A1/en active Pending
- 2017-04-21 PT PT177866944T patent/PT3445397T/pt unknown
- 2017-04-21 DK DK17786694.4T patent/DK3445397T3/da active
- 2017-04-21 CA CA3018990A patent/CA3018990A1/en active Pending
- 2017-04-21 FI FIEP17786694.4T patent/FI3445397T3/fi active
- 2017-04-21 BR BR112018071686-3A patent/BR112018071686A2/pt active Search and Examination
- 2017-04-21 JP JP2018555114A patent/JP7072521B2/ja active Active
-
2018
- 2018-09-27 ZA ZA2018/06449A patent/ZA201806449B/en unknown
- 2018-10-19 MX MX2021013783A patent/MX2021013783A/es unknown
-
2019
- 2019-04-15 US US16/384,087 patent/US10550199B2/en active Active
- 2019-12-26 US US16/727,151 patent/US10870707B2/en active Active
-
2022
- 2022-05-10 JP JP2022077485A patent/JP2022116013A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514367A5 (cg-RX-API-DMAC7.html) | ||
| RU2018140971A (ru) | Дисплей интерального мембранного белка на внеклеточных оболочечных вирионах поксвируса | |
| Melero et al. | Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development | |
| JP2015212284A5 (cg-RX-API-DMAC7.html) | ||
| JP2019033754A5 (cg-RX-API-DMAC7.html) | ||
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| JP2005120106A5 (cg-RX-API-DMAC7.html) | ||
| HUP0002070A2 (hu) | Alternatív módon célba juttatott adenovírus | |
| JP2007535912A5 (cg-RX-API-DMAC7.html) | ||
| JP2015514811A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514522A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503198A5 (cg-RX-API-DMAC7.html) | ||
| WO2022089471A1 (zh) | 一种β冠状病毒多聚体抗原、其制备方法和应用 | |
| JP2008524261A5 (cg-RX-API-DMAC7.html) | ||
| JP2016508143A5 (cg-RX-API-DMAC7.html) | ||
| Masuda et al. | Stable trimer formation of spike protein from porcine epidemic diarrhea virus improves the efficiency of secretory production in silkworms and induces neutralizing antibodies in mice | |
| CN104845981B (zh) | 田鼠巴贝虫Bm1524抗原及其应用 | |
| CN116143888A (zh) | 非洲猪瘟病毒p30蛋白抗原表位多肽及其应用 | |
| CN115368443A (zh) | 非洲猪瘟病毒CD2v蛋白B细胞线性表位及应用 | |
| RU2017145246A (ru) | Рекомбинантный белок, содержащих антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (ВАРИАНТЫ) | |
| JP2015524420A5 (cg-RX-API-DMAC7.html) | ||
| NZ794089B2 (en) | Integral membrane protein display on poxvirus extracellular enveloped virions | |
| RU2010125678A (ru) | Способ получения рекомбинантной вакцины | |
| WO2019039602A1 (ja) | タンパク質、及び当該タンパク質を含む担体を用いる抗体又はその断片の単離方法 | |
| JP2024508587A (ja) | Ａａｖ２親和剤 |